CoChat

Patient-derived xenografts and organoids model therapy response in prostate cancer

Open access
Karkampouna, Sofia, La Manna, Federico, Benjak, Andrej, Kiener, Mirjam, De Menna, Marta, Zoni, Eugenio, Grosjean, Joël, Klima, Irena, Garofoli, Andrea, Bolis, Marco, Vallerga, Arianna, Theurillat, Jean-Philippe, De Filippo, Maria R., Genitsch, Vera, Keller, David, Booij, Tijmen H., Stirnimann, Christian U., Eng, Kenneth, Sboner, Andrea, Ng, Charlotte K. Y., Piscuoglio, Salvatore, Gray, Peter C., Spahn, Martin, Rubin, Mark A., Thalmann, George N., Kruithof-de Julio, Marianna · 2021 · Nature Communications
Cited by 161

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined, due to lack of experimental models that mimic different disease stages. We describe an androgen-dependent PCa patient-derived xenograft (PDX) model from treatment-naïve, soft tissue metastasis (PNPCa). RNA and whole-exome sequencing of the PDX tissue and organoids confirmed transcriptomic and genomic similarity to primary tumor. PNPCa harbors BRCA2 and CHD1 somatic mutations, shows an SPOP/FOXA1 -like transcriptomic signature and microsatellite instability, which occurs in 3% of advanced PCa and has never been modeled in vivo. Comparison of the treatment-naïve PNPCa with additional metastatic PDXs (BM18, LAPC9), in a medium-throughput organoid screen of FDA-approved compounds, revealed differential drug sensitivities. Multikinase inhibitors (ponatinib, sunitinib, sorafenib) were broadly effective on all PDX- and patient-derived organoids from advanced cases with acquired resistance to standard-of-care compounds. This proof-of-principle study may provide a preclinical tool to screen drug responses to standard-of-care and newly identified, repurposed compounds.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-21300-6

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 161

Metadata

Authors
Karkampouna, S., La Manna, F., Benjak, A., Kiener, M., De Menna, M., Zoni, E., Grosjean, J., Klima, I., Garofoli, A., Bolis, M., Vallerga, A., Theurillat, J.-P., De Filippo, M. R., Genitsch, V., Keller, D., Booij, T. H., Stirnimann, C. U., Eng, K., Sboner, A., Ng, C. K. Y., Piscuoglio, S., Gray, P. C., Spahn, M., Rubin, M. A., Thalmann, G. N., & Kruithof-de Julio, M.
Venue
Nature Communications
Published
2021-02-18
Volume
12
Issue
1
Pages
1117-1117
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3131787684
Cited by
161
References
11
FWCI
15.04
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient-derived xenografts and organoids model therapy response in prostate cancer. https://app.cochat.ai/papers/10.1038/s41467-021-21300-6
The paper
Karkampouna, S., La Manna, F., Benjak, A., Kiener, M., De Menna, M., Zoni, E., Grosjean, J., Klima, I., Garofoli, A., Bolis, M., Vallerga, A., Theurillat, J.-P., De Filippo, M. R., Genitsch, V., Keller, D., Booij, T. H., Stirnimann, C. U., Eng, K., Sboner, A., . . . Kruithof-de Julio, M. (2021). Patient-derived xenografts and organoids model therapy response in prostate cancer. Nature Communications. https://doi.org/10.1038/s41467-021-21300-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.